Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGNDZ) Assets Average (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Assets Average for 15 consecutive years, with $1.5 billion as the latest value for Q4 2025.

  • Quarterly Assets Average rose 60.15% to $1.5 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.5 billion through Dec 2025, up 60.15% year-over-year, with the annual reading at $1.3 billion for FY2025, 44.73% up from the prior year.
  • Assets Average hit $1.5 billion in Q4 2025 for Ligand Pharmaceuticals, up from $1.2 billion in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $1.5 billion in Q4 2025 to a low of $763.7 million in Q3 2023.
  • Historically, Assets Average has averaged $1.0 billion across 5 years, with a median of $937.7 million in 2024.
  • Biggest five-year swings in Assets Average: crashed 34.5% in 2023 and later surged 60.15% in 2025.
  • Year by year, Assets Average stood at $1.3 billion in 2021, then fell by 29.48% to $906.6 million in 2022, then fell by 14.16% to $778.2 million in 2023, then increased by 21.86% to $948.3 million in 2024, then skyrocketed by 60.15% to $1.5 billion in 2025.
  • Business Quant data shows Assets Average for LGNDZ at $1.5 billion in Q4 2025, $1.2 billion in Q3 2025, and $927.0 million in Q2 2025.